Roivant Sciences $150 million equity offering
We advised the company on its debut SEC-registered primary and secondary offering
Davis Polk advised Roivant Sciences Ltd. in connection with its debut SEC-registered offering of 30,000,000 of its common shares by Roivant and certain selling shareholders.
Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch “Vants” – nimble and focused biopharmaceutical and health technology companies. It became a publicly traded company in 2021 through a combination with Montes Archimedes Acquisition Corp.
The Davis Polk corporate team included partner Derek Dostal and associate Soo Kyung Chae. Counsel Sarah E. Kim and Matthew R. Silver provided 1940 Act advice. Partners Po Sit, Jonathan Cooklin and Kara L. Mungovan and associates Yixuan Long, Freddie Schwier and Dmitry Dobrovolskiy provided tax advice. Members of the Davis Polk team are based in the New York and London offices.